In the phase III trial CLEOPATRA, adding pertuzumab to trastuzumab plus docetaxel in the first line setting significantly prolonged both progression free survival (PFS) and overall survival (OS) of patients with HER2+ advanced BC (aBC), with a median OS of more than 56 months in pertuzumab-treated patients [8]. This evidence concerns the gene ERBB2 and breast cancer.